OVER TWO DECADES OF MAKING A DIFFERENCE IN THE FIGHT AGAINST PEDIATRIC CANCER
The Caitlin Robb Foundation was founded over two decades ago based upon several initial beliefs related to an ongoing and diligent understanding of our beneficiaries and to keeping our generous supporters informed as to how their donations are routed to those beneficiaries.
In 2017, through the combined giving of the Arizona and Delaware Valley Chapters, the Caitlin Robb Foundation re-established its prior relationship with Memorial Sloan Kettering Cancer Center (MSK) by gifting $50,000 to support the ambitious research and clinical agenda of Nai-Kong V. Cheung, MD, PhD, Head of MSK’s Neuroblastoma Program. This gift brings the Foundation’s total giving to MSK to $137,000 and incorporates a plan to partner with MSK in the years to come. Foundation Founder and Chairman Ross Robb said “Among the several high-quality centers of neuroblastoma research across America, we are impressed by the ongoing progress of Dr. Cheung’s work and his commitment to both research and clinical outcomes at Memorial Sloan Kettering.”
Because of the pioneering work done within the Department of Pediatrics at MSK, more than 50 percent of patients treated there survive the disease, as compared to fewer than five percent in the 1980s. MSK’s physician-scientists have made great strides in developing safer and more-effective therapies for patients with neuroblastoma.
Delaware Valley Chapter President, Jack Jones commented that “it is noteworthy that the Delaware Valley and Arizona Chapters combined in supporting Memorial Sloan Kettering. In 2018 and beyond, we hope to more closely integrate efforts between the Chapters to continue to support state-of-the-art research and the needs of patients and families fighting this terrible disease.”
Dr. Chueng tells us that, “the generous philanthropy of the Caitlin Robb Foundation continues to have a measurable impact on our ambitious goal of curing neuroblastoma, driving the development of pioneering therapies that will safely eradicate disease and allow for a bright future for our patients and their families.”